Shukra Pharmaceuticals Adjusts Outlook Amid Mixed Financial Performance and Growth Potential

Jul 01 2025 08:17 AM IST
share
Share Via
Shukra Pharmaceuticals has recently adjusted its evaluation, reflecting a shift in its technical outlook. The company has shown strong performance metrics, including a 28.73% return over the past year, despite facing challenges like declining net sales and profits. It maintains a low Debt to EBITDA ratio, indicating solid debt servicing capacity.
Shukra Pharmaceuticals, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the technical landscape, moving from a sideways trend to a mildly bullish outlook.

The company's stock has shown notable performance metrics over various periods. For instance, it has generated a return of 28.73% over the past year, significantly outpacing the broader market, which recorded a return of 5.79% during the same timeframe. Additionally, Shukra Pharmaceuticals has demonstrated impressive long-term growth, with an annual operating profit increase of 60.53%.

Despite these positive indicators, the company has faced challenges, including a decline in net sales and profits over recent quarters. The latest figures show net sales for the first nine months at Rs 29.41 crore, reflecting a decrease of 45.95%, while profit after tax for the latest six months stands at Rs 8.55 crore, down 36.24%.

Furthermore, Shukra Pharmaceuticals maintains a low Debt to EBITDA ratio of 1.28 times, indicating a strong capacity to service its debt. However, the stock's valuation appears high, trading at a premium compared to its peers, with a Price to Book Value ratio of 11.6.

For those interested in further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News